Supernus Pharmaceuticals (SUPN) Announces Issuance Of First Use Patents Protecting SPN-812 As A Novel Non-Stimulant ADHD Product
1/27/2014 8:51:05 AM
ROCKVILLE, Md., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a European patent (number 2341912) and Canadian patent (number 2,735,934) for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
Help employers find you! Check out all the jobs and post your resume.
comments powered by